Polyclonal Antibody to Semaphorin 3A (SEMA3A)
| Code | Size | Price |
|---|
| PAL917Ra01-20ul | 20ul | £97.00 |
Quantity:
| PAL917Ra01-100ul | 100ul | £187.00 |
Quantity:
| PAL917Ra01-200ul | 200ul | £254.00 |
Quantity:
| PAL917Ra01-1ml | 1ml | £590.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
SEMAL; Hsema-I; Hsema-III; SEMA1; SEMAD; SEMAIII; SemD; Coll-1; Sema Domain,Immunoglobulin Domain(Ig),Transmembrane Domain(TM)and Short Cytoplasmic Domain 3A
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Semaphorin 3A
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:300-1200
Immunohistochemistry: 5-20ug/mL;1:30-120
Immunocytochemistry: 5-20ug/mL;1:30-120
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:30-120
Immunocytochemistry: 5-20ug/mL;1:30-120
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Semaphorin 3A (SEMA3A) | RPL917Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||